Pfizer's most recent trend suggests a bullish bias. One trading opportunity on Pfizer is a Bull Put Spread using a strike $44.50 short put and a strike $39.50 long put offers a potential 7.07% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $44.50 by expiration. The full premium credit of $0.33 would be kept by the premium seller. The risk of $4.67 would be incurred if the stock dropped below the $39.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Pfizer is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Pfizer is bullish.
The RSI indicator is at 76.2 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Pfizer
What AbbVie’s Valuation Trend Indicates
Thu, 04 Oct 2018 19:09:07 +0000
In October, of the total 21 analysts covering AbbVie (ABBV), nine have given the stock “buy” or higher ratings, ten have given it “hold” ratings, and two have given it “sell” ratings.
Seattle Genetics: Impact of the Cascadian Acquisition
Thu, 04 Oct 2018 17:25:47 +0000
Seattle Genetics’ (SGEN) net investment and other income increased from $2.91 million in the second quarter of 2017 to $106.56 million in the second quarter of 2018 due to net gains from its sale of Immunomedics common shares. As a result, the company posted a net income of $76.27 million in the second quarter—compared to a net loss of $56.36 million in the second quarter of 2017.
Antares Pharma Is Expected to Report Positive EPS in 2019
Thu, 04 Oct 2018 16:50:02 +0000
In H1 2018, Antares Pharma (ATRS) reported a loss per share of $0.07, which was higher by $0.02 on a year-over-year (or YoY) basis. Losses increased due to rising operating expenses and an unfavorable shift in product mix. The company reported operating expenses of $22.25 million in H1 2018, a YoY rise of 6%, which is mainly attributable to a 12% YoY rise in research and development expenses associated with pipeline products.
Amgen’s Stock Performance and Estimates after Q3 2018
Thu, 04 Oct 2018 14:31:25 +0000
Amgen (AMGN) is a biotechnology company that focuses on discovering, developing, and delivering drugs in therapeutic areas such as cardiovascular, neuroscience, and oncology. The chart below compares Amgen’s EPS and revenues since the first quarter of 2017, as well as its third-quarter estimates.
5 Reasons Why Investors Should Bet on Pfizer (PFE) Stock
Thu, 04 Oct 2018 13:49:01 +0000
Here are five aspects that investors may consider while investing in Pfizer's (PFE) stock.
Also on Market Tamer…
Follow Us on Facebook